Mark H Kirschbaum

Mark H Kirschbaum

UNVERIFIED PROFILE

Are you Mark H Kirschbaum?   Register this Author

Register author
Mark H Kirschbaum

Mark H Kirschbaum

Publications by authors named "Mark H Kirschbaum"

Are you Mark H Kirschbaum?   Register this Author

14Publications

203Reads

17Profile Views

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

Clin Cancer Res 2014 Jan 31;20(2):490-8. Epub 2013 Oct 31.

Authors' Affiliations: The University of Chicago; Decatur Memorial Hospital, Decatur; Illinois Cancer Care, Peoria; Loyola University Medical Center, Maywood, Illinois; University of California, San Francisco, San Francisco; City of Hope, Duarte, California; University of Michigan Medical Center, Ann Arbor, Michigan; Medical College of Wisconsin, Milwaukee, Wisconsin; and National Cancer Institute, Rockville, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310865PMC
January 2014

A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.

Biol Blood Marrow Transplant 2012 Mar 27;18(3):432-40. Epub 2011 Jul 27.

Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2011.07.017DOI Listing
March 2012

Histone deacetylase inhibitors and Hodgkin's lymphoma.

Lancet Oncol 2011 Dec;12(13):1178-9

Nevada Cancer Institute, Las Vegas, NV 89135, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(11)70327-8DOI Listing
December 2011

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Blood 2011 Jun 25;117(22):5827-34. Epub 2011 Feb 25.

Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health/DHHS, 6130 Executive Blvd., Rockville, MD 20852, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2010-10-31
Publisher Site
http://dx.doi.org/10.1182/blood-2010-10-312603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112033PMC
June 2011

Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.

Cancer Res 2011 Jun 18;71(11):3912-20. Epub 2011 Apr 18.

Department of Translational Research, Clinical and Molecular Pharmacology, City of Hope and Beckman Research Institute, Duarte, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-2259DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107377PMC
June 2011

Lessons of war: progress in transplant conditioning regimens.

Leuk Lymphoma 2007 Dec;48(12):2300-1

Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190701742498DOI Listing
December 2007